Anavex Life Sciences Corp (AVXL)

[drv17]

Falconer - Dr. Kaufman is more than just on the SAB (Startegic Advisory Board.
NEW YORK – January 2, 2019 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced the appointment of Walter E Kaufmann, MD to Chief Medical Officer (CMO)

It appears to me that he will be deeply involved in the trenches with his great expertise.